Prevention committee

ESGO Prevention 2

The Prevention Committee was established in 2019 to fulfil the ESGO vision: Best treatment and prevention in gynaecological cancer. ESGO has set as its mission to improve the health and well-being of women with gynaecological cancers through prevention, research, excellence in care and education. The Prevention Committee is therefore one of the cornerstones to ensure the fulfilment of its mission.

The Chair of the Prevention Committee is Prof. Murat Gultekin.

Committee Goals

  • Facilitate systematic research, issue scientific publications, and disseminate findings in the prevention and treatment of pre-invasive diseases.
  • Raise public and governmental awareness and advocate about gynaecological cancers, their prevention and treatment through ENGAGe.
  • Collaborate with professional societies, patient advocacy organisations, policymakers and other stakeholders to advance gynaecological cancers prevention and care.
  • Contribute to cervical cancer elimination in Europe in line with the WHO elimination programme 2030. Decrease mortality and extend life of gynaecological cancer patients in line with the EU Beat the cancer plan.

Committee Motto

  • Filling the scientific gap by providing scientific evidence on topics related to prevention and treatment of pre-invasive disease
  • Bridging the East and the West by sharing the expertise of ESGO professionals with colleagues in Lower and Middle Income Countries via virtual conferences, webinars, and on-site screening pilot projects

Committee Structure

Prevention Committee Chair: Murat Gultekin

 

 

 

 

 

 

Members:

Marc Arbyn, Utku Akgor, Esat Bilal, Nicolo Bizzarri, Sarah Bowden, Laia Bruni, Laura Burney Ellis, Murat Cengiz, Kimon Chatzistamatiou, Volkan Ege, Dimitrios Haidopulos, Houssein El Hajj, Nicolo Gallio, Omar Gassama, Livia Giordano, Charlotte Goutallier, Mihaela Grigore, Reda Hemida, Elmar Joura, Joana Kacperczyk-Bartnik, Vesna Kesic, Maria Kyrgiou, Belen Lopez, Edina Lukacs, Claudia Marchetti, Anita Mitra, Nagham Ibraheem Mahdi, Afraa Mahjoob Al-Naddawi, Gadelkareem Nassar, Eva-Maria Niine-Roolaht, Patrick Petignat, Alejandra Picconi, Mario Preti, Zoia Razumova, Jalid Sehouli, Aleksandra Shavrova, Nadja Taumberger, Charalampos Theofanakis, Icó Tóth, Andreas Ullrich, Zvi Vaknin, Alexandra Wagner, Ignacio Zapardiel

HPV prevention in pregnancy - 9th May 2024 -

Recording available HERE

All Prevention Committee webinars are available on the eAcademy portal

Click on the link to see them all.

Committee Publications

Publications 2024
  • Genital tract microbiota composition profiles and use of prebiotics and probiotics in gynaecological cancer prevention: review of the current evidence, the European Society of Gynaecological Oncology prevention committee statement, The European Society of Gynaecological Oncology (ESGO) Prevention Committee Statement. M. Kyrgiou, December 2023, published in Lancet Microbe
Publications 2023
Publications 2021
Publications 2020
Publications 2019

Cooperation with key stakeholders

 

World Health Organization has launched ''Cervical Cancer Elimination Program'' on November 19, 2020.

The program asks the countries to vaccinate the girls under 15 years of age (90% coverage), to screen females by minimal two times when they are 35 and 45 (70%) coverage and to treat the lesions detected appropriately (in 90% of cases).

Modelling studies show that if all countries can implement the program until 2030 and can achieve these targets, there will be a 30% reduction in cervical cancer mortality by 2030 and the cervical cancer may be eliminated until the end of this century (namely incidence less than 4 \ 100.000).

 

ESGO Prevention committee has joined in to fulfil the WHO cervical cancer elimination strategy as a leading European actor in prevention.


European projects

RISCC: Risk-based Screening for Cervical Cancer

ESGO/ENGAGe is involved in the Horizon 2020 RISCC project.

Within the RISCC project ESGO / ENGAGe is responsible for the co-creation of the e-health/m-health platform for risk based cervical cancer screening and for the dissemination of the results to 12 ENGAGe member countries. This project is planned for five years and intended to terminate in 2025.

For more information about the ESGO/ENGAGe involvement please use the following link.